| Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas TY Seiwert, Z Zuo, MK Keck, A Khattri, CS Pedamallu, T Stricker, C Brown, ... Clinical cancer research 21 (3), 632-641, 2015 | 660 | 2015 |
| MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to aurora kinase inhibition G Mollaoglu, MR Guthrie, S Böhm, J Brägelmann, I Can, PM Ballieu, ... Cancer cell 31 (2), 270-285, 2017 | 459 | 2017 |
| Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes MK Keck, Z Zuo, A Khattri, TP Stricker, CD Brown, M Imanguli, D Rieke, ... Clinical cancer research 21 (4), 870-881, 2015 | 377 | 2015 |
| K-ras mutation subtypes in NSCLC and associated co-occuring mutations in other oncogenic pathways M Scheffler, MA Ihle, R Hein, S Merkelbach-Bruse, AH Scheel, ... Journal of Thoracic Oncology 14 (4), 606-616, 2019 | 205 | 2019 |
| Web-TCGA: an online platform for integrated analysis of molecular cancer data sets M Deng, J Brägelmann, JL Schultze, S Perner BMC bioinformatics 17, 1-7, 2016 | 178 | 2016 |
| FirebrowseR: an R client to the Broad Institute’s Firehose Pipeline M Deng, J Brägelmann, I Kryukov, N Saraiva-Agostinho, S Perner Database 2017, baw160, 2017 | 171 | 2017 |
| Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors J Fassunke, F Müller, M Keul, S Michels, MA Dammert, A Schmitt, ... Nature communications 9 (1), 4655, 2018 | 129 | 2018 |
| PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma T Müller, M Braun, D Dietrich, S Aktekin, S Höft, G Kristiansen, F Göke, ... Oncotarget 8 (32), 52889, 2017 | 114 | 2017 |
| RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma DVT Catenacci, G Cervantes, S Yala, EA Nelson, E El-Hashani, R Kanteti, ... Cancer biology & therapy 12 (1), 9-46, 2011 | 105 | 2011 |
| Pan-cancer analysis of the mediator complex transcriptome identifies CDK19 and CDK8 as therapeutic targets in advanced prostate cancer J Brägelmann, N Klümper, A Offermann, A Von Maessenhausen, D Böhm, ... Clinical Cancer Research 23 (7), 1829-1840, 2017 | 93 | 2017 |
| Structural alterations of MET trigger response to MET kinase inhibition in lung adenocarcinoma patients D Plenker, M Bertrand, AJ de Langen, R Riedel, C Lorenz, AH Scheel, ... Clinical Cancer Research 24 (6), 1337-1343, 2018 | 83 | 2018 |
| Family matters: How MYC family oncogenes impact small cell lung cancer J Brägelmann, S Boehm, MR Guthrie, G Mollaoglu, TG Oliver, ML Sos Cell Cycle 16 (16), 1489-1498, 2017 | 78 | 2017 |
| Performance of the CHARGE-AF risk model for incident atrial fibrillation in the EPIC Norfolk cohort R Pfister, J Brägelmann, G Michels, NJ Wareham, R Luben, KT Khaw European journal of preventive cardiology 22 (7), 932-939, 2015 | 73 | 2015 |
| MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer MA Dammert, J Brägelmann, RR Olsen, S Böhm, N Monhasery, ... Nature communications 10 (1), 3485, 2019 | 64 | 2019 |
| Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors D Plenker, M Riedel, J Brägelmann, MA Dammert, R Chauhan, ... Science translational medicine 9 (394), eaah6144, 2017 | 63 | 2017 |
| Recurrent HNSCC harbor an immunosuppressive tumor immune microenvironment suggesting successful tumor immune evasion C Watermann, H Pasternack, C Idel, J Ribbat-Idel, J Braegelmann, ... Clinical cancer research 27 (2), 632-644, 2021 | 61 | 2021 |
| Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA J Brägelmann, I Dagogo-Jack, M El Dinali, T Stricker, CD Brown, Z Zuo, ... Oral oncology 49 (6), 525-533, 2013 | 57 | 2013 |
| Mechanisms of Primary Drug Resistance in FGFR1-Amplified Lung Cancer F Malchers, M Ercanoglu, D Schütte, R Castiglione, V Tischler, S Michels, ... Clinical Cancer Research 23 (18), 5527-5536, 2017 | 56 | 2017 |
| Systematic kinase inhibitor profiling identifies CDK9 as a synthetic lethal target in NUT midline carcinoma J Brägelmann, MA Dammert, F Dietlein, JM Heuckmann, A Choidas, ... Cell reports 20 (12), 2833-2845, 2017 | 47 | 2017 |
| Elevated FSP1 protects KRAS-mutated cells from ferroptosis during tumor initiation F Müller, JKM Lim, CM Bebber, E Seidel, S Tishina, A Dahlhaus, J Stroh, ... Cell Death & Differentiation 30 (2), 442-456, 2023 | 41 | 2023 |
Sven PernerPathology, UKSH Campus Luebeck and Research Center BorstelDirección de correo verificada de uksh.de
